New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GSK;SI;FLO;NOK;UBS From The Last 14 Days
Check below for free stories on GSK;SI;FLO;NOK;UBS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 8, 2014
11:55 EDTNOKNokia advances after securing Chinese approval for Microsoft deal
Subscribe for More Information
11:03 EDTGSKPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
10:28 EDTNOKHigh option volume stocks: GIMO SOCL SPLK NOK CSOD
Subscribe for More Information
09:09 EDTNOKOn The Fly: Pre-market Movers
HIGHER: BioScrip (BIOS), up 6.7% after stock was named as a stock pick and a potential takeover target by Oscar Schafer while speaking on CNBC... Nokia (NOK), up 5% after deal to sell substantially all of its Devices & Services business to Microsoft (MSFT) receives regulatory approval in China... Ctrip.com (CTRP), up 4.6% after Bloomberg said, citing sources, that the company is in talks with Baidu-controlled (BIDU) Qunar (QUNR) about a partnership or a potential merger... Plug Power (PLUG), up 4.6% after CEO discusses plan to expand fuel cells to trucks in interview... FireEye (FEYE), up 2.5% following upgrade at Wedbush... Twitter (TWTR), up 2% following initiation of coverage with a Buy rating at at Janney Capital... Nike (NKE), up 1.75% after upgraded at Stifel. LOWER: Gigamon (GIMO), down 23% after lowering revenue outlook, shares downgraded at Pacific Crest... LivePerson (LPSN), down 3% after announcing resignation of EVP, Worldside Sales, shares downgraded at Benchmark... Cisco (CSCO), down 0.5% following downgrade to Hold from Buy at Wunderlich.
09:00 EDTNOKNokia rises 5%
Nokia is up 5%, or 36c, to $7.58
08:46 EDTGSKTeva announces first approval, launch of generic Lovaza capsules in the U.S.
Teva (TEVA) announces the approval of the generic equivalent to Lovaza in the United States. Teva believes it is first-to-file and thus far is the only company to receive an approval from FDA. Teva plans to commence shipping immediately. Lovaza Capsules, marketed by GlaxoSmithKline (GSK), had annual sales of approximately $1.1B in the United States, according to IMS data as of December 2013.
07:22 EDTGSKCaSA-ISPE to hold a conference
21st Annual Lilfe Sciences Technology Conference is being held in Raleigh, North Carolina on April 8.
05:45 EDTNOKNokia, Microsoft receive approval from China for Devices & Services transaction
Subscribe for More Information
April 7, 2014
14:18 EDTGSKGlaxoSmithKline reports 14.1% stake in Applied Genetic Technologies
Subscribe for More Information
13:08 EDTUBSPanel rules UBS unit to pay $5.4M to ex-broker, Reuters says
A Financial Industry Regulation Authority arbitration panel ruled that a unit of UBS has to pay $5.4M to an ex-broker to settle a dispute which stemmed from the sale of Lehman structured notes to his clients, reported Reuters. Reference Link
06:58 EDTUBSDark markets could cause more harm than high-frequency trading, Reuters says
After a book by financial author Michael Lewis sparked worries that high-speed traders have been rigging the U.S. stock market, former regulators and academics say a more serious threat to investors could be the increasing amount of trading that happens outside of exchanges, reported Reuters. Top internalizers include units of KCG Holdings (KCG), Citadel, UBS (UBS), and Citigroup (C). Dark pool operators include Credit Suisse (CS) and Morgan Stanley (MS). In an attempt to earn back some of the retail orders, exchanges such as IntercontinentalExchange Group's (ICE) New York Stock Exchange, Nasdaq (NDAQ), and BATS Global Markets, have allowed brokerages to place dark pool-style orders on their platforms, with the trade hidden until after it is executed. Reference Link
06:23 EDTNOKDelta Air Lines to equip flight attendants with Nokia Lumia 1520
Delta Air Lines (DAL) this fall will equip more than 20,000 flight attendants with handheld Nokia (NOK) Lumia 1520 phablets, which will serve as their on-board manual and in-flight sales device as well as a platform for future, more personalized in-flight customer service. The Lumia 1520 features a larger format, 6-inch screen and will replace the smaller Lumia 820 already in the hands of Delta on-board professionals.
April 6, 2014
16:23 EDTGSKGlaxoSmithKline investigates bribery allegations in Iraq, WSJ says
GlaxoSmithKline is investigating allegations of bribery by employees in Iraq, says the Wall Street Journal, citing emails reviewed by the publication. Reference Link
April 4, 2014
07:30 EDTUBSUBS battles proposal to move Puerto Rico bond fund cases, Reuters says
A unit of UBS is fighting a plan that would allow hundreds of investors who lost money in closed-end Puerto Rico bond funds to arbitrate their claims against the firm on the U.S. mainland, according to Reuters, citing people familiar with the matter. Reference Link
06:29 EDTGSKGlaxoSmithKline cuts China employees amid probe, WSJ reports
According to a source, as it deals with a bribery probe in Beijing, GlaxoSmithKline is cutting employees in China, the Wall Street Journal reports. It is unclear how many of Glaxo's 7,000 employees in China have been let go. Reference Link
April 3, 2014
09:37 EDTGSKAmgen to pay GlaxoSmithKline $275M to terminate denosumab collaboration pact
Subscribe for More Information
April 2, 2014
09:18 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
07:44 EDTGSKAgenus down 9.4% after GlaxoSmithKline stops MAGRITi Phase 3 trial
Subscribe for More Information
06:11 EDTGSKGlaxoSmithKline confirms plans to stop MAGRIT Phase III trial
GlaxoSmithKline announced its decision to stop the MAGRITi trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer patients, after establishing that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment. Data from the trial announced on 20 March 2014 showed that it did not meet its first or second co-primary endpoints as it did not significantly extend disease-free survival when compared to placebo in either the overall MAGE-A3 positive population or in those MAGE-A3-positive patients who did not receive chemotherapy. The trial will be stopped and GSK will now gain access to the un-blinded data, in order to conduct a full assessment of the findings and understand learnings for other aspects of immunotherapy development within GSK. The Independent Data Monitoring Committee indicated that its review of the current safety information revealed no specific safety concern and the data is in line with the known safety information for the MAGE-A3 cancer immunotherapeutic.
05:45 EDTGSKAgenus announces GSK's MAGE-A3 Phase 3 study will be stopped
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use